The MarketWatch News Department was not involved in the creation of this content. In Canada, LEQEMBI(R) is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive ...
The Alzheimer Society of Ontario calls for immediate system investments to support access to the newly approved dementia treatment TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The Alzheimer Society of ...
NKGen Biotech activates two new clinical trial sites for Alzheimer's treatment, enhancing patient access and recruitment for troculeucel therapy. NKGen Biotech, Inc. has announced the activation of ...
Health Canada has conditionally approved the drug lecanemab to slow early-stage Alzheimer's disease, raising questions about its effectiveness and availability in Canada. Lecanemab is a lab-made ...
Five hundred people in the Canadian province of New Brunswick were diagnosed with a "mystery brain disorder" that resembled prion disease; a 2025 study offered explanations, but some patients rejected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results